- Home
- FTDR vs HCM Comparison
FTDR vs HCM Comparison
Compare FTDR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- HCM
- Stock Information
- Founded
- FTDR 1971
- HCM 2000
- Country
- FTDR United States
- HCM Hong Kong
- Employees
- FTDR N/A
- HCM N/A
- Industry
- FTDR Diversified Commercial Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- HCM Health Care
- Exchange
- FTDR Nasdaq
- HCM Nasdaq
- Market Cap
- FTDR 2.9B
- HCM 2.5B
- IPO Year
- FTDR 2018
- HCM N/A
- Fundamental
- Price
- FTDR $53.12
- HCM $14.21
- Analyst Decision
- FTDR Hold
- HCM Hold
- Analyst Count
- FTDR 5
- HCM 1
- Target Price
- FTDR $46.50
- HCM $19.00
- AVG Volume (30 Days)
- FTDR 871.8K
- HCM 82.7K
- Earning Date
- FTDR 05-01-2025
- HCM 03-19-2025
- Dividend Yield
- FTDR N/A
- HCM N/A
- EPS Growth
- FTDR 34.69
- HCM N/A
- EPS
- FTDR 3.08
- HCM 0.04
- Revenue
- FTDR $1,891,000,000.00
- HCM $630,201,000.00
- Revenue This Year
- FTDR $11.77
- HCM $14.86
- Revenue Next Year
- FTDR $6.46
- HCM $19.54
- P/E Ratio
- FTDR $17.24
- HCM $68.70
- Revenue Growth
- FTDR 5.58
- HCM N/A
- 52 Week Low
- FTDR $32.95
- HCM $11.51
- 52 Week High
- FTDR $63.49
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- FTDR 79.82
- HCM 45.83
- Support Level
- FTDR $40.11
- HCM $14.18
- Resistance Level
- FTDR $53.97
- HCM $14.84
- Average True Range (ATR)
- FTDR 1.70
- HCM 0.57
- MACD
- FTDR 1.42
- HCM -0.03
- Stochastic Oscillator
- FTDR 94.41
- HCM 1.94
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.